

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

1646

DATE MAILED: 06/10/2003

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/759,152 01/16/2001 Michelle A.J. Palmer 4085-235-27 CIP 2836 7590 06/10/2003 PIPER MARBURY RUDNICK & WOLFE LLP Supervisor, Patent Prosecution Services **EXAMINER** 1200 Nineteenth Street, N.W. ULM, JOHN D Washington, DC 20036-2412 **ART UNIT** PAPER NUMBER

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/759,152

Applicant(s)

Palmer et al.

Examiner

John Ulm

Art Unit

 	· · · · · · · · · · · · · · · · · · ·		John Ulm	1646	
	The MAILING DATE of this	s communication appears	on the cover sheet with the corre		
				spondence addr	ess
	HORTENED STATUTORY PER MAILING DATE OF THIS COI	MIMITATION		H(S) FROM	
mailir	ng date of this communication.	rovisions of 37 CFR 1.136 (a). In	no event, however, may a reply be timely filed	d after SIX (6) MONTH	IS from the
- If NO - Failure - Any re earne	period for reply specified above is less than period for reply is specified above, the max re to reply within the set or extended period reply received by the Office later than three ad patent term adjustment. See 37 CFR 1.7	n thirty (30) days, a reply within the common statutory period will apply a	he statutory minimum of thirty (30) days will be and will expire SIX (6) MONTHS from the mailing the application to become ABANDONED (35 U.S his communication, even if timely filed, may re	e considered timely.	
Status					
	and to communicate	on(s) filed on <u>Mar 20, 2</u>	003		
2a) ∐	THE COLON IS THERE.	2b) This acti	ion is non-final.		·
3)□	Since this application is in co	ondition for allowance e	xcept for formal matters, prosecte Quayle, 1935 C.D. 11, 450	Cution as to the	marite is
	tion of Claims	ie practice under <i>Ex par</i>	te Quayle, 1935 C.D. 11; 453	0.G. 213.	inents is
	Claim(s) 1-60				
			is/are	pending in the	application.
5\□	Claim (s) 2-5,	. 11, 12, 14, 16, 17, 1	9-23, 30-47, and 55-60 is/are	withdrawn fro	m consideration.
				s/are allowed.	
6) <u> </u> X	Claim(s) 1, 6-10, 13, 15, 18,	24, 25, 29, 48-50, and	d EA		
7) 💢	Claim(s) 26-28 and 51-53			s/are rejected.	
8) 🗌	Claims		is		
Applicat	tion Papers		are subject to restrict	ion and/or elec	tion requirement.
9) 🗌	The specification is objected t	to by the Examiner			
10) 🗌	The drawing(s) filed on	is/are a			
	Applicant may not request that	any objection to the de-) ☐ accepted or b) ☐ objected	to by the Exam	niner.
11)	The proposed drawing correct	tion filed on	wing(s) be held in abeyance. See	37 CFR 1.85(a).	
	If approved, corrected drawings	s are required in reply to	is: a) approved b)∐ disapproved	by the Examiner.
12) 🗌 🗇	The oath or declaration is obje	ected to by the Evenine	this Office action.	,	
Priority u	Inder 35 U.S.C. §§ 119 and 1	20	:r.		
13) 🗌 🗡	Acknowledgement is made of	a claim for foreign prior	rity under 35 U.S.C. § 119(a)-(d		į
a) 🗌	All b) Some* c) No	one of:	119(a)-(c	l) or (f).	
1.	Certified copies of the pri	Ority documents have t	Neep received		j
2.	☐ Certified copies of the pri	ority documents have b	peen received in Application No.		
3.	- cobies of the celtitied cut	DIRS Of the priority deal			·
*See	the attached detailed Office a	action for a list of the co	ertified conies not received		ge
,	exhaust is made of a	a claim for domestic price	Ority under 35 U.S.C. 5 440/-		
	The translation of the foreign	language provisional ar	Inlication has been asset to	•	
	and thought light in ade of a	claim for domestic price	ority under 35 U.S.C. §§ 120 ar	nd/or 121	}
		·		14/01 121,	
	of References Cited (PTO-892)	4) [Interview Summary (PTO-413) Paper No(s)	•	
3) Informe	of Draftsperson's Patent Drawing Review (F	PIO-948) 51 [Notice of Informal Patent Application (PTO-	152)	
	etion Disclosure Statement(s) (PTO-1449) P	la	Other:		

Art Unit: 1646

- 1) Claims 1 to 60 are pending in the instant application. Claims 1 to 26 have been amended and claims 27 to 60 have been added as requested by Applicant in Paper Number 17, filed 20 March of 2003.
- 2) A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 20 March of 2003 has been entered.
- 3) Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.
- 4) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 5) Claims 2 to 5, 14, 30 to 47 and 55 to 60 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 10.
- Claims 11, 12, 16, 17 and 19 to 23 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 12.

Art Ûnit: 1646

- 7) The instant specification does not comply with 37 C.F.R. § 1.821(d) which requires a reference to a particular sequence identifier (SEQ ID NO:) be made in the specification and claims wherever a reference is made to that sequence. The instant specification refers to the amino sequence "GGGGS" numerous times without employing the required sequence identifier. Correction is required. See M.P.E.P. 2422.03.
- Applicant is advised that should claim 29 be found allowable, claim 54 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).
- 9) Claims 6 to 8 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for those reasons of record as applied to claims 1, 6 to 13 and 15 to 25 in section 7 of Paper Number 11 and claims 6 to 8 in section 6 of Paper Number 14. As stated and repeated therein, a critical element of the disclosed invention is the requirement that each member of a pair of interacting proteins be fused to one member of a pair of complementary β-galactosidase mutants. This critical feature is lacking from the instant claims. Applicant's traversal of this rejection on the premise that the critical elements are provided by the instant specification and a general knowledge of the art completely ignores the basis upon which this rejection was made.

Art Únit: 1646

- U.S.C. 103(a) as being unpatentable over the Blau et al. patent (6,342,345 B1) in view of the Barak et al. patent (5,891,646, cited by Applicant) the Kovoor et al. publication (J. Biol. Chem. 274(11):6831-6834, 12 Mar. 1999, cited by Applicant), the Gurevich et al. '95 publication (J. Biol. Chem. 270(2):720-731, 13 Jan. 1995, cited by Applicant) and the Gurevich et al. '97 publication (Mol. Pharm. 51:161-169, 1997) for those reasons of record as applied to claims 1, 6 to 10, 13, 15, 18, 24 and 25 in section 10 of Paper Number 12 and section 7 of Paper Number 14. Applicant's arguments in traversal of this rejection essentially repeat those arguments of record which were answered section 7 of Paper Number 14.
- Claims 26 to 28 and 51 to 53 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Whereas the text in line 49 of column 11 of Blau et al. described the use of a linker to join a binding partner to one of the complementary β -galactosidase mutants described therein, the art of record did not disclose any advantage to employing the specific linker recited in the instant claims in the construction of such a fusion protein.
- 12) Applicant's arguments filed 20 March of 2003 have been fully considered but they are not persuasive for those reasons given above.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

Art-Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1800